What Stage C (Advanced, BCLC-C) Means
Vascular invasion or extrahepatic spread, PS 0–1
Treatment Approach for Stage C (Advanced, BCLC-C)
Sorafenib, lenvatinib, atezolizumab+bevacizumab. Clinical trials. Immunotherapy emerging. Palliative.
Survival Rates and Prognosis
The 5-year survival rate for liver cancer at Stage C (Advanced, BCLC-C) is approximately 5-year: 10–20%. Survival rates are statistical averages drawn from large patient populations and may not reflect your individual outcome. Factors that influence your specific prognosis include your age, overall health, tumour biology, and how well the cancer responds to treatment.
Important: These numbers are drawn from historical data. Newer treatments available today may improve outcomes beyond what published statistics show. Discuss your individual prognosis with your oncologist.
How Other Stages Compare
| Stage | 5-Year Survival | Treatment |
|---|---|---|
| Stage 0 (Very early, BCLC-0) | 5-year: 70–80% | Resection, ablation (RFA/MWA), or transplant. Adjuvant therapy per protocol…. |
| Stage A (Early, BCLC-A) | 5-year: 50–70% | Resection, ablation, TACE, or transplant. Consider adjuvant therapy. Curative… |
| Stage B (Intermediate, BCLC-B) | 5-year: 30–50% | TACE, sequential TACE + sorafenib. Lenvatinib emerging option. Consider… |
| Stage D (Terminal, BCLC-D) | 5-year: <5% | Best supportive care, palliative care focus. Consider clinical trials if… |
Liver Cancer Treatment in Top Cities
Diagnosed with Stage C (Advanced, BCLC-C) Liver Cancer?
Our specialists can review your reports and create a personalised treatment plan.
Get a Free ConsultationAll Liver Cancer stages Liver Cancer overview
VICI Healthcare is for informational purposes only and does not replace professional medical advice. Always consult a qualified oncologist.